Ruolo dei Checkpoint Inhibitors in Oncologia
Alessandro Inno
(Si ringrazia l’oncologo Alessandro Inno per aver accettato di mettere a disposizione dei colleghi questa presentazione di sua proprietà).
Download della presentazione in formato PDF
CONTENUTI DELLA PRESENTAZIONE
(presentazione con contenuti in inglese)
-
The Cancer-Immunity Cycle
-
Immune Checkpoints
-
T-cell targets for immunoregulatory antibody therapy
-
Blockade of CTLA-4 and PD-1/PD-L1 Signaling
-
Cancer Immunotherapy
-
FDA Approval Timeline of Checkpoint Inhibitors
-
5-yr Follow-Up of Nivolumab in previously treated advanced NSCLC (CA209-003 study)
-
How to raise the bar in Immuno-Oncology?
-
-
PD-L1 as a Biomarker in advanced NSCLC
-
Towards Personalized Medicine in Immuno-Oncology
-
IO-based Combinations
-
IO/CTx combination in NSCLC
-
-
-
Toxicity of Checkpoint Inhibitors
-
Immune-Related Adverse Events
-
Incidence of irAEs with anti-CTLA4 and anti-PD1/PDL1 agents
-
Toxicity of Combinations
-
In Summary, Checkpoint Inhibitors…
Download della presentazione in formato PDF